These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12667554)

  • 1. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
    Evans KD; Lau ST; Oberbauer AM; Martin RB
    Bone; 2003 Mar; 32(3):268-74. PubMed ID: 12667554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
    Camacho NP; Raggio CL; Doty SB; Root L; Zraick V; Ilg WA; Toledano TR; Boskey AL
    Calcif Tissue Int; 2001 Aug; 69(2):94-101. PubMed ID: 11683430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
    McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
    Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta.
    Evans KD; Sheppard LE; Rao SH; Martin RB; Oberbauer AM
    Int J Biomed Sci; 2009 Dec; 5(4):345-52. PubMed ID: 23675157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.
    Bargman R; Huang A; Boskey AL; Raggio C; Pleshko N
    Connect Tissue Res; 2010 Apr; 51(2):123-31. PubMed ID: 20053133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
    Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
    Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
    Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
    Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
    Camacho NP; Carroll P; Raggio CL
    Calcif Tissue Int; 2003 May; 72(5):604-9. PubMed ID: 12574874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
    Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
    J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
    Shi C; Sun B; Ma C; Wu H; Chen R; He H; Zhang Y
    Biomed Res Int; 2021; 2021():4243105. PubMed ID: 33506016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
    Meganck JA; Begun DL; McElderry JD; Swick A; Kozloff KM; Goldstein SA; Morris MD; Marini JC; Caird MS
    Bone; 2013 Sep; 56(1):204-12. PubMed ID: 23774443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
    Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
    J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
    Delos D; Yang X; Ricciardi BF; Myers ER; Bostrom MP; Camacho NP
    J Orthop Res; 2008 Feb; 26(2):153-64. PubMed ID: 17729310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the
    Shanas N; Querido W; Oswald J; Jepsen K; Carter E; Raggio C; Pleshko N
    Appl Spectrosc; 2022 Apr; 76(4):416-427. PubMed ID: 34643134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse.
    Kalajzic I; Terzic J; Rumboldt Z; Mack K; Naprta A; Ledgard F; Gronowicz G; Clark SH; Rowe DW
    Endocrinology; 2002 May; 143(5):1594-601. PubMed ID: 11956140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.
    Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL
    Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim).
    Grabner B; Landis WJ; Roschger P; Rinnerthaler S; Peterlik H; Klaushofer K; Fratzl P
    Bone; 2001 Nov; 29(5):453-7. PubMed ID: 11704498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility.
    Carriero A; Doube M; Vogt M; Busse B; Zustin J; Levchuk A; Schneider P; Müller R; Shefelbine SJ
    Bone; 2014 Apr; 61():116-24. PubMed ID: 24373921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.